H.C. Wainwright analyst Joseph Pantginis initiated coverage of ProKidney (PROK) with a Buy rating and $12 price target The company is pioneering an approach to postponing progressive kidney dysfunction, the analyst tells investors in a research note. The firm says ProKidney is a late clinical-stage biopharmaceutical company developing rilparencel, an investigational autologous cell therapy targeting patients with moderate to severe chronic kidney disease and type 2 diabetes. It believes rilparencel has the potential to redefine the therapeutic landscape of chronic kidney disease.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PROK:
- PROK Upcoming Earnings Report: What to Expect?
- ProKidney reports Q3 EPS (12c), consensus (14c)
- ProKidney presents results from Phase 2 REGEN-007 trial of rilparencel
- Prokidney’s REACT Study: A Potential Game Changer for Kidney Disease Treatment
- Prokidney’s Long-Term Study on REACT Therapy: A Potential Game-Changer for CKD